Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting
- PMID: 20118030
- PMCID: PMC6201308
- DOI: 10.1188/10.CJON.81-86
Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting
Abstract
Older patients with cancer who may be more susceptible than younger patients to the myelosuppressive effects of chemotherapy undergo dose delays and reductions that can compromise treatment outcomes. Incidence of neutropenic complications and suboptimal chemotherapy delivery can be reduced with prophylactic colony-stimulating factors; however, their use in older patients with cancer has not been well studied. A randomized, multicenter, community-based trial was designed to compare prophylactic pegfilgrastim use (all cycles of chemotherapy) versus its more common reactive use (at clinicians' discretion) in patients aged 65 years or older with various cancers. Pegfilgrastim use in all cycles reduced the incidence of febrile neutropenia by about 60% and hospitalizations caused by neutropenia and febrile neutropenia by about 50% versus reactive pegfilgrastim use in later cycles. The study showed that older patients with cancer can be treated safely with optimal doses of chemotherapy with appropriate supportive care. Nurses, key collaborators in providing supportive care, can take an active role in identifying older patients who may benefit from pegfilgrastim in all cycles of chemotherapy.
References
-
- Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer. 2006;42:2433–2453. doi: 10.1016/j.ejca.2006.05.002. - DOI - PubMed
-
- Balducci L, Extermann M. Management of cancer in the older person: A practical approach. Oncologist. 2000;5:224–237. - PubMed
-
- Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB, American Society of Clinical Oncology Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. Journal of Clinical Oncology. 2003;21:937–941. doi: 10.1200/JCO.2003.07.165. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical